The GJB1 gene encodes connexin 32 (Cx32), a gap junction protein critical for direct cell-to-cell communication, particularly in myelinating cells of the peripheral and central nervous systems.
Mutations in GJB1 cause X-linked Charcot-Marie-Tooth disease type 1 (CMT1X), a hereditary neuropathy characterized by muscle weakness, sensory loss, and variable involvement of the central nervous system.
The GJB1 gene encodes a protein called connexin 32 (Cx32). This protein is a vital part of gap junctions, channels connecting neighboring cells. These channels allow ions, nutrients, and signaling molecules to pass directly from one cell to another, essential for healthy nerve function.
Gene Location: X chromosome
Protein Product: Connexin 32 (Cx32)
Tissue Expression: Nervous system (Schwann cells and oligodendrocytes), liver, pancreas, and kidney
Connexin 32 is especially important in myelinating Schwann cells of the peripheral nervous system (PNS) and plays a supporting role in oligodendrocytes in the central nervous system (CNS).
Gap junctions are formed when two connexons (hemichannels) from adjacent cells dock together. Each connexon is made of six connexin proteins.
These structures allow fast and direct cell-to-cell communication by letting small molecules and ions pass freely.
In the PNS, Schwann cells wrap around axons to form the myelin sheath, which insulates nerves and speeds up signal transmission.
Connexin 32 is found in specific regions of Schwann cells—especially in non-compact myelin areas like the Schmidt-Lanterman incisures and paranodes—where it helps maintain the health of the myelin sheath by allowing communication between the inner and outer layers of the cell.
Charcot-Marie-Tooth disease (CMT) is the most common inherited condition that affects the nerves. It causes weakness and shrinking of muscles, especially in the lower legs and feet, along with numbness or loss of feeling.
People often start noticing symptoms in childhood or teenage years, and the condition usually progresses slowly over time.
There are several types of CMT, grouped based on how the nerves are damaged:
Over 100 genes have been linked to CMT, but most cases are due to just a few key genes.
GJB1 genetic mutations cause CMTX1, an X-linked form of CMT. In this type:
Some GJB1 mutations will include, or primarily manifest with, CNS symptoms.
There is no cure for CMT yet, but treatment can help manage the symptoms. Treatment may include:
Some people may be able to join clinical trials that test new treatments.
CMT usually does not shorten life, but it can affect a person’s ability to walk, work, or do everyday activities. How fast it gets worse depends on the type and when symptoms begin.
With the right care and support, many people with CMT can lead full and active lives.
Genetic testing for GJB1 mutations may be appropriate in the following settings:
GJB1 mutations are a common cause of CMT1X, an inherited peripheral neuropathy. Testing is appropriate for individuals with:
CMT1X follows an X-linked inheritance pattern. Males who inherit a pathogenic GJB1 mutation typically develop symptoms of the disease because they have only one X chromosome.
In contrast, females who carry the mutation on one of their two X chromosomes may be carriers. Due to a process called X-inactivation, carrier females may show mild symptoms or remain asymptomatic.
Genetic testing is valuable in families with a history of CMT, as it can confirm carrier status in females and help assess the risk of passing the mutation to children.
CMT has multiple genetic causes. GJB1 testing helps distinguish CMT1X from other CMT types and acquired neuropathies.
Genetic counseling is recommended before and after testing to explain inheritance patterns, interpret results, and guide family planning.
Testing for GJB1 is performed as a genetic test to look for mutations in the gene that would alter functional protein availability. The following section outlines the testing procedures and interpretation.
Genetic testing involves blood, saliva, or cheek swab samples, although specialized laboratories may recommend different sample types.
A cheek swab or saliva sample is easily obtained from the comfort of home, while blood samples typically require a blood draw.
Normal reference ranges for GJB1 genetic testing are considered to be without mutations that can alter the activity of the GJB1 proteins.
Specific GJB1 mutations may have the following clinical significance:
Identifying a pathogenic (disease-causing) mutation in the GJB1 gene confirms a diagnosis of CMT1X in males and carrier status in females. This is a key step in providing an accurate diagnosis and guiding management for affected individuals and their families.
CMT1X is inherited in an X-linked manner. Males who carry a GJB1 mutation (hemizygous) typically show the classic symptoms of the disorder, such as progressive muscle weakness and sensory loss. Males will pass on the affected gene to all daughters, but no sons.
Females with a mutation (heterozygous) may have milder symptoms or may not show any symptoms at all, depending on how the mutation is expressed due to X-chromosome inactivation.
Carrier females have a 50% chance of passing on the affected gene to offspring.
Severity and symptoms can vary based on the specific GJB1 mutation. Some variants cause only peripheral symptoms; others may involve the CNS.
The absence of pathogenic variants means that GJB1 mutations are not the cause of observed symptoms. A negative test result may also carry the following significance:
A negative result does not rule out inherited neuropathy. Other genes may be involved.
If clinical suspicion remains high, wider testing, such as expanded genetic panels or whole exome/genome sequencing, should be considered.
Click here to compare genetic test panels and order genetic testing for health-related SNPs.
Abrams CK. GJB1 Disorders: Charcot-Marie-Tooth Neuropathy (CMT1X) and Central Nervous System Phenotypes. 1998 Jun 18 [Updated 2024 Apr 25]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1374/
Chu, F., Xu, J., Wang, Y., Li, Y., Wang, Y., Liu, Z., & Li, C. (2022). Novel mutations in GJB1 trigger intracellular aggregation and stress granule formation in X-linked Charcot-Marie-Tooth Disease. Frontiers in Neuroscience, 16. https://doi.org/10.3389/fnins.2022.972288
Dere, E., & Margraf, J. (2012). The role of gap junctions in the brain in health and disease. Neuroscience & Biobehavioral Reviews, 36(1), 206–217. https://doi.org/10.1016/j.neubiorev.2011.05.015
GJB1 gene: MedlinePlus Genetics. (n.d.). Medlineplus.gov. https://medlineplus.gov/genetics/gene/gjb1/
GJB1 gap junction protein beta 1 [Homo sapiens (human)] - Gene - NCBI. (2025). Nih.gov. https://www.ncbi.nlm.nih.gov/gene/2705
Hammi C, Yeung B. Neuropathy. [Updated 2022 Oct 15]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK542220/
Li, M., Yin, M., Yang, L., Chen, Z., Du, P., Sun, L., & Chen, J. (2022). A novel splicing mutation in 5’UTR of GJB1 causes X‐linked Charcot—Marie–tooth disease. Molecular Genetics & Genomic Medicine, 11(3). https://doi.org/10.1002/mgg3.2108
Nagappa M, Sharma S, Taly AB. Charcot-Marie-Tooth Disease. [Updated 2024 Jun 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK562163/
Niu, J., Dai, Y., Liu, M., Li, Y., Ding, Q., Guan, Y., Cui, L., & Jin, L. (2020). GJB1 Mutation-A Disease Spectrum: Report of Case Series. Frontiers in Neurology, 10. https://doi.org/10.3389/fneur.2019.01406
Tomaselli, P. J., Rossor, A. M., Horga, A., Jaunmuktane, Z., Carr, A., Saveri, P., Piscosquito, G., Pareyson, D., Laura, M., Blake, J. C., Poh, R., Polke, J., Houlden, H., & Reilly, M. M. (2017). Mutations in noncoding regions of GJB1 are a major cause of X-linked CMT. Neurology, 88(15), 1445–1453. https://doi.org/10.1212/wnl.0000000000003819